ECI2 (Gene)

Organism:

Homo sapiens

Synonyms:ACBD2, DRS-1, DRS1, ECI2, ENTREZ:10455, HCA88, HGNC:14601, MIM:608024, NM_001166010, NM_006117, NM_206836, NP_001159482, NP_006108, NP_996667, NR_028588, PECI, XM_006714957, XM_017010170, XP_006715020, XP_016865659, dJ1013A10.3, enoyl-CoA delta isomerase 2

Omim:OMIM:608024

Id:ENSG00000198721

Hgnc:HGNC:14601

Entrez:10455

Ensembl:ENSG00000198721

Description:enoyl-CoA delta isomerase 2

This gene encodes a member of the hydratase/isomerase superfamily. The protein encoded is a key mitochondrial enzyme involved in beta-oxidation of unsaturated fatty acids. It catalyzes the transformation of 3-cis and 3-trans-enoyl-CoA esters arising during the stepwise degradation of cis-, mono-, and polyunsaturated fatty acids to the 2-trans-enoyl-CoA intermediates. Alternatively spliced transcript variants have been described. [provided by RefSeq, Aug 2011]

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View ECI2's neighborhood in the knowledge graph.

Submit

Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with ECI2.

CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using ECI2.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for ECI2.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with ECI2.

Results found

Linked to

	Label	Description
	GSE135514 8 V 7 DASATINIB HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE216273,GSE216292 14 V 6 PALBOCICLIB HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE252944 AKT inhibition 10 v 15 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE186471 1 V 2 CARNOSOL HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE203362 0 V 1 ENZALUTAMIDE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE208634 1 V 2 DOXYCYCLINE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE233679 12 V 0 NICOTINAMIDE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE216043 10 V 5 CISPLATIN HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE128730 3 V 5 NERATINIB HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE172016 2 V 0 PACLITAXEL HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS

GSE135514 8 V 7 DASATINIB HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE216273,GSE216292 14 V 6 PALBOCICLIB HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE252944 AKT inhibition 10 v 15 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE186471 1 V 2 CARNOSOL HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE203362 0 V 1 ENZALUTAMIDE HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE208634 1 V 2 DOXYCYCLINE HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE233679 12 V 0 NICOTINAMIDE HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE216043 10 V 5 CISPLATIN HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE128730 3 V 5 NERATINIB HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE172016 2 V 0 PACLITAXEL HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

DISPLAY PER PAGE

CFDE Workbench

Consortium

Community

Resources

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

Consortium

Community

Resources

CFDE Workbench

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.